Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)
CLI-06001AA1-05
Phase 3 small_molecule active
Quick answer
Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®) for Chronic Obstructive Pulmonary Disease (COPD) is a Phase 3 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A
- Indication
- Chronic Obstructive Pulmonary Disease (COPD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active